Case report: Recurrent disseminated intravascular coagulation caused by intermittent dosing of rifampin

American Journal of Tropical Medicine and Hygiene

Volumn 86, Issue 2, 2012, Pages 264-267

  Havey, Thomas C ^a   Cserti Gazdewich, Christine ^a   Sholzberg, Michelle ^b   Keystone, Jay S ^a   Gold, Wayne L ^a  

^a TORONTO GENERAL HOSPITAL   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DAPSONE; FRESH FROZEN PLASMA; MINOCYCLINE; OFLOXACIN; RIFAMPICIN;

ABDOMINAL PAIN; AGED; ARTICLE; CASE REPORT; CLINICAL FEATURE; DIARRHEA; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG EXPOSURE; DRUG INTERMITTENT THERAPY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FEVER; HEMATEMESIS; HEMODIALYSIS; HEMOLYSIS; HUMAN; HYPOTENSION; KIDNEY BIOPSY; KIDNEY TUBULE NECROSIS; LEPROSY; MONOTHERAPY; NAUSEA; RECURRENT DISEASE; SIDE EFFECT; VOMITING; CHEMICALLY INDUCED DISORDER; DOSE RESPONSE; HEMOLYTIC ANEMIA; REVIEW;

MYCOBACTERIUM LEPRAE;

ABDOMINAL PAIN; AGED; ANEMIA, HEMOLYTIC; DISSEMINATED INTRAVASCULAR COAGULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FEVER; HUMANS; HYPOTENSION; LEPROSY; RIFAMPIN; VOMITING;

EID: 84856992530     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.2012.11-0598     Document Type: Article

References (18)

1. Johnson ST, Fueger JT, Gottschall JG, 2007. One center's experience; the serology and drugs associated with drug-induced hemolytic anemia - a new paradigm. Transfusion 47: 697-702. (Pubitemid 46449631)
2. Forget EJ, Menzies D, 2006. Adverse reactions to first-line antituberculosis drugs. Expert Opin Drug Saf 5: 231-249. (Pubitemid 43379622)
3. World Health Organization, 1994. Chemotherapy of Leprosy: Report of a WHO Study Group -WHO Technical Report Series No. 847. Available at: http://www.who.int/lep/mdt/chemotherapy/en/index.html. Accessed November 1, 2011.
4. Martinez E, Muniz E, Domingo P, 1994. Evidence implicating rifampin-independent antiplatelet antibodies in the pathogenesis of rifampin-induced immune thrombocytopenia. Clin Infect Dis 19: 351-353. (Pubitemid 24258947)
5. Worlledge S, 1973. Rifampicin-induced antibodies. Chemotherapy 4: 273-278.
6. Grosset J, Leventis S, 1983. Adverse effects of rifampin. Rev Infect Dis 5: S440-S446.
7. De Vriese AS, Robbrecht DL, Vanholder RC, Vogelaers DP, Lameire NH, 1998. Rifampicin-associated acute renal failure: pathophysiologic, immunologic, and clinical features. Am J Kidney Dis 31: 108-115. (Pubitemid 28116691)
8. A Hong Kong Tuberculosis Treatment Services/Brompton Hospital/British Medical Research Council Investigation, 1974. A controlled clinical trial of small weekly doses of rifampicin in the prevention of adverse reactions to the drug in a once-weekly regimen of chemotherapy in Hong Kong: a second report: the results at 12 months. Tubercle 55: 193-210.
9. Riska N, Mattson K, 1972. Adverse reactions during rifampicin treatment. Scand J Respir Dis 53: 87-96.
10. Brasil MT, Opromolla DV, Marzliak ML, Nogueira W, 1996. Results of a surveillance system for adverse effects in leprosy's World Health Organization/Multidrug Therapy. Int J Lepr 64: 97-104.
11. Denis J, Robert A, Johanet C, Homberg JC, Opolon P, Levy VG, 1983. Immunoallergic reaction to rifampicin with disseminated intravascular coagulation. Presse Med 12: 1479-1481. (Pubitemid 13098593)
12. Fujita M, Kunitake R, Nagano Y, Maeda F, 1997. Disseminated intravascular coagulation associated with pulmonary tuberculosis. Intern Med 36: 218-220. (Pubitemid 27249729)
13. Ip M, Cheng KP, Cheung WC, 1991. Disseminated intravascular coagulopathy associated with rifampicin. Tubercle 72: 2913.
14. Luzzati R, Giacomazzi D, Franchi F, Barcobello M, Vento S, 2007. Life-threatening, multiple hypersensitivity reactions induced by rifampicin in one patient with pulmonary tuberculosis. South Med J 100: 854-855.
15. Nowicka J, Kotschy M, Chwistecki K, Jelen M, 1977. Disseminated intravascular coagulation (DIC) during superacute haemolysis in a patient with ovarian dermatoid cyst treated with rifampicin. Haematologia (Budap) 11: 359-364. (Pubitemid 9062822)
16. Namisato M, Ogawa H, 2000. Serious side effects of rifampin on the course of World Health Organization/Multidrug Treatment: a case report. Int J Lepr Other Mycobact Dis 68: 277-282. (Pubitemid 32151851)
17. Souza CS, Alberto PL, Foss NT, 1997. Disseminated intravascular coagulopathy as an adverse reaction to intermittent rifampin schedule in the treatment of leprosy. Int J Lepr Other Mycobact Dis 65: 366-370.
18. Dacso M, Jacobson RR, Stryjewska BM, Prestigiacomo J, Scollard DM, 2011. Evaluation of multi-drug therapy for leprosy in the USA using daily rifampin. South Med J 104: 1-6.